Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SRZN vs IBO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SRZN Captures Overall Composite Edge (32.8 SELL vs 36.8 SELL), While IBO Leads 3–2 on Growth & Valuation Pillars
SRZN Overall Winner
6-Pillar Tally: SRZN 2 – 3 IBO (1 Tie)
Matrix Metrics: SRZN 5 – 4 IBO
As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Impact BioMedical, Inc. (IBO) on higher Unified Composite conviction (32.8/100 SELL vs. 36.8/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while IBO wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $32.32 (N/M Forward P/E, -485.4% operating margin) versus IBO at $4.91 (N/M Forward P/E, -12621.0% operating margin).
- Composite vs. Pillar Nuance: While IBO currently prints a higher short-term Unified Composite Score (36.8/100 SELL vs. SRZN 32.8/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -12621.0% operating margin) and revenue trajectory (+408.6% vs. +16.7% YoY).
- Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both SRZN (32.8/100 SELL) and IBO (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SRZN vs IBO
SRZN
Head-to-Head Winner
Surrozen, Inc. Common
$32.32
+2.25% 1D
Market Cap
$602.5M
TTM Revenue
$11M
Forward P/E
N/M
Beta / 30D Vol
1.21β · 62% Vol
Unified Composite Score
32.8
SELL
Tech 50.0
Fund 32.0
Flow 64.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
IBO
Impact BioMedical, Inc.
$4.91
-4.47% 1D
Market Cap
$44.4M
TTM Revenue
$2.6M
Forward P/E
N/M
Beta / 30D Vol
-6.72β · 120% Vol
Unified Composite Score
36.8
SELL
Tech 15.0
Fund 32.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 IBO)
1. Valuation Multiples
IBO
Forward P/E
N/M
N/M
Trailing P/E
N/M
0.4x
PEG Ratio
N/M
N/M
EV / Revenue
48.3x
17.4x
2. Growth & Scale
SRZN
Revenue Growth (YoY)
+408.6%
+16.7%
Earnings Growth (YoY)
-37.0%
+0.0%
TTM Revenue (USD)
$11M
$2.6M
Market Cap
$602.5M
$44.4M
3. Profitability & Quality
IBO
Gross Margin
N/A
N/A
Operating Margin
-485.4%
-12621.0%
Net Profit Margin
0.0%
4247.4%
Return on Equity (ROE)
-62.8%
71.2%
4. Balance Sheet & Cash Flow
IBO
Cash Generation (TTM)
-$31M
-$284M EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$95M Net Cash
$1.18 Book/Sh · 71.2% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SRZN
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
72.0% (5th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SRZN (5) vs IBO (4)| Institutional Metric | SRZN | IBO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $602.5M | $44.4M | SRZN | |
| Trailing P/E Ratio | N/M | 0.4x | IBO | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +408.6% | +16.7% | SRZN | |
| Operating Margin (TTM) | -485.4% | -12621.0% | SRZN | |
| Net Profit Margin | 0.0% | 4247.4% | IBO | |
| Return on Equity (ROE) | -62.8% | 71.2% | IBO | |
| 52-Week Range Position | 79% ($12–$38) | 67% ($0–$7) | SRZN | |
| Beta / 30D Volatility | 1.21β · 62% Vol | -6.72β · 120% Vol | SRZN | |
| Unified Institutional Score | 32.8 / 100 (SELL) | 36.8 / 100 (SELL) | IBO | |
| Trailing 12M Revenue (USD) | $11M | $2.6M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 48.3x EV/Rev | N/M PEG · 17.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$31M ($95M Net Cash) | -$284M EBITDA ($1.18 Book/Sh · 71.2% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
IBO +45.33 pp
3M Horizon
IBO +910.01 pp
6M Horizon
IBO +794.35 pp
1Y Horizon
IBO +696.08 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | IBO Revenue | SRZN Op. Margin | IBO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2022 | $10M | $0M | -354.7% | -6808.0% | SRZN |
| FY2024 | $10M | N/A | -239.7% | N/A | SRZN |
| FY2025 | $0M | $0M | -1210.6% | -13381.2% | SRZN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SRZN
CONSOLIDATION
Current IV
72.0%
IV Percentile
5th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
IBO
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SRZN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
IBO Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SRZN vs IBO Key Questions & Quantitative Answers
As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Impact BioMedical, Inc. (IBO) on higher Unified Composite conviction (32.8/100 SELL vs. 36.8/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while IBO wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $32.32 (N/M Forward P/E, -485.4% operating margin) versus IBO at $4.91 (N/M Forward P/E, -12621.0% operating margin). Composite vs. Pillar Nuance: While IBO currently prints a higher short-term Unified Composite Score (36.8/100 SELL vs. SRZN 32.8/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -12621.0% operating margin) and revenue trajectory (+408.6% vs. +16.7% YoY). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both SRZN (32.8/100 SELL) and IBO (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with IBO at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (N/A gross margin, -12621.0% operating margin). Across the 3-period historical trajectory (FY2022 to FY2025), SRZN cumulative revenue shifted +0.0% while IBO shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBO.
IBO screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 17.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus IBO (71.2% ROE) capital efficiency.
In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk). By comparison, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.72β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
IBO vs SRZN · Reverse Pair
SRZN vs FTH
· Sector Peer
SRZN vs JSPR
· Sector Peer
SRZN vs TIL
· Sector Peer
IBO vs PLRZ
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma